Tags

Type your tag names separated by a space and hit enter

Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Am J Hematol. 2003 Sep; 74(1):26-31.AJ

Abstract

Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU). A total of 58 patients (29 PV, 14 ET, 12 IMF, 3 unclassified) had been treated with HU. Thirty-five of these patients had been treated with HU alone whereas 18 patients had received both HU and BU. The follow-up period was 7.8 years. Twenty-five patients had not been treated with HU. In this patient group, 4 patients had been treated with BU. The follow-up period was 10.5 years. In the HU-treated group (n = 58) 7 patients developed AML and 5 patients MDS. Five of the 12 patients had been treated with HU alone, and 4 patients had received both HU and BU. In the non-HU-treated group (n = 25) 1 patient with PV developed acute myeloid leukemia (AML). This patient had only been treated with phlebotomies. It is concluded that treatment with HU is leukemogenic, with an incidence of AML and MDS of approximately 14% when used alone. The incidence is markedly increased to about 30% when HU is preceded by treatment with BU. HU is not recommended for use in younger patients, in whom non-leukemogenic agents such as alpha-interferon and anagrelide should be used instead.

Authors+Show Affiliations

Department of Hematology L, Rigshospitalet University Hospital, Copenhagen, Denmark.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12949887

Citation

Nielsen, Iben, and Hans Carl Hasselbalch. "Acute Leukemia and Myelodysplasia in Patients With a Philadelphia Chromosome Negative Chronic Myeloproliferative Disorder Treated With Hydroxyurea Alone or With Hydroxyurea After Busulphan." American Journal of Hematology, vol. 74, no. 1, 2003, pp. 26-31.
Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol. 2003;74(1):26-31.
Nielsen, I., & Hasselbalch, H. C. (2003). Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. American Journal of Hematology, 74(1), 26-31.
Nielsen I, Hasselbalch HC. Acute Leukemia and Myelodysplasia in Patients With a Philadelphia Chromosome Negative Chronic Myeloproliferative Disorder Treated With Hydroxyurea Alone or With Hydroxyurea After Busulphan. Am J Hematol. 2003;74(1):26-31. PubMed PMID: 12949887.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. AU - Nielsen,Iben, AU - Hasselbalch,Hans Carl, PY - 2003/9/2/pubmed PY - 2003/10/3/medline PY - 2003/9/2/entrez SP - 26 EP - 31 JF - American journal of hematology JO - Am J Hematol VL - 74 IS - 1 N2 - Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU). A total of 58 patients (29 PV, 14 ET, 12 IMF, 3 unclassified) had been treated with HU. Thirty-five of these patients had been treated with HU alone whereas 18 patients had received both HU and BU. The follow-up period was 7.8 years. Twenty-five patients had not been treated with HU. In this patient group, 4 patients had been treated with BU. The follow-up period was 10.5 years. In the HU-treated group (n = 58) 7 patients developed AML and 5 patients MDS. Five of the 12 patients had been treated with HU alone, and 4 patients had received both HU and BU. In the non-HU-treated group (n = 25) 1 patient with PV developed acute myeloid leukemia (AML). This patient had only been treated with phlebotomies. It is concluded that treatment with HU is leukemogenic, with an incidence of AML and MDS of approximately 14% when used alone. The incidence is markedly increased to about 30% when HU is preceded by treatment with BU. HU is not recommended for use in younger patients, in whom non-leukemogenic agents such as alpha-interferon and anagrelide should be used instead. SN - 0361-8609 UR - https://www.unboundmedicine.com/medline/citation/12949887/Acute_leukemia_and_myelodysplasia_in_patients_with_a_Philadelphia_chromosome_negative_chronic_myeloproliferative_disorder_treated_with_hydroxyurea_alone_or_with_hydroxyurea_after_busulphan_ DB - PRIME DP - Unbound Medicine ER -